Yang Xi, Wei Ri-Bao, Wang Yang, Su Ting-Yu, Li Qing-Ping, Yang Ting, Huang Meng-Jie, Li Kun-Ying, Chen Xiang-Mei
Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China (mainland).
Med Sci Monit. 2017 Feb 6;23:673-681. doi: 10.12659/msm.903102.
BACKGROUND The effects of low serum C3 levels and the activation of the complement system on the development and the prognosis of IgAN are unclear. The present study aimed to determine whether decreased levels of complement C3 influence the prognosis of IgAN patients with chronic kidney disease. MATERIAL AND METHODS We enrolled a total of 1564 patients with primary IgAN diagnosed by renal biopsy at the Chinese PLA General Hospital from January 2011 to March 2015. The endpoint was end-stage renal disease (ESRD) or a doubling of the baseline serum creatinine (D-SCr) level. All patients were using 1: 1 propensity score matching (PSM), and the baseline values were not significantly different between these 2 groups (P>0.05). RESULTS During a follow-up period, 14 patients in the group with decreased C3 levels reached the endpoint, with 12 patients with normal C3 levels. There was no significant difference between the 2 groups in achieving D-SCr or ESRD (P=0.676). In multivariate Cox analysis, adjusted for demographic and laboratory examination, the risk of reaching the endpoint was comparable in the 2 groups (HR, 0.70; 95% CI, 0.27-1.78; P=0.449;). Furthermore, the risk of reaching ESRD (HR, 0.83; 95% CI, 0.25-2.75; P=0.757) and D-SCr (HR, 1.45; 95% CI, 0.20-10.60; P=0.718) did not differ between the 2 groups. CONCLUSIONS Decreased serum C3 levels in IgA nephropathy with chronic kidney disease did not play a decisive role in renal progression.
背景 低血清C3水平及补体系统激活对IgA肾病发生发展及预后的影响尚不清楚。本研究旨在确定补体C3水平降低是否影响慢性肾脏病IgA肾病患者的预后。材料与方法 我们纳入了2011年1月至2015年3月在中国人民解放军总医院经肾活检确诊的1564例原发性IgA肾病患者。终点为终末期肾病(ESRD)或基线血清肌酐(D-SCr)水平翻倍。所有患者采用1:1倾向评分匹配(PSM),两组间基线值无显著差异(P>0.05)。结果 在随访期间,C3水平降低组有14例患者达到终点,C3水平正常组有12例患者达到终点。两组在达到D-SCr或ESRD方面无显著差异(P=0.676)。在多因素Cox分析中,经人口统计学和实验室检查校正后,两组达到终点的风险相当(HR,0.70;95%CI,0.27-1.78;P=0.449)。此外,两组在达到ESRD(HR,0.83;95%CI,0.25-2.75;P=0.757)和D-SCr(HR,1.45;95%CI,0.20-10.60;P=0.718)方面的风险无差异。结论 慢性肾脏病IgA肾病患者血清C3水平降低在肾脏进展中未起决定性作用。